Editors' comments on a new trial of activated protein C for persistent septic shock.
Jordi
J
Mancebo
Massimo
M
Antonelli
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic / Q000941:ethics / Q000379:methods; D004345:Drug Industry / Q000941:ethics; D006801:Humans; D015337:Multicenter Studies as Topic / Q000941:ethics / Q000379:methods; D010919:Placebos; D011486:Protein C / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000941:ethics / Q000379:methods; D011994:Recombinant Proteins / Q000627:therapeutic use; D012107:Research Design; D012772:Shock, Septic / Q000188:drug therapy* / Q000401:mortality; D014481:United States / Q000453:epidemiology
D000890:Anti-Infective Agents; D010919:Placebos; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated